<unk>  is a fixed-dose combination of<unk> , a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor,<unk> , an HCV NS5A inhibitor, and<unk> , an HCV NS3/4A protease inhibitor that is FDA approved for the treatment of treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing<unk>  without an NS5A inhibitor. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include headache, fatigue, diarrhea, and nausea.
Sofosbuvir / velpatasvir / voxilaprevir
Ombitasvir / paritaprevir / ritonavir / dasabuvir
Ledipasvir / sofosbuvir
Elbasvir / grazoprevir
Glecaprevir / pibrentasvir
Dolutegravir / rilpivirine
Bictegravir / emtricitabine / tenofovir alafenamide
Ombitasvir, paritaprevir, and ritonavir